Comparative Pharmacology
Head-to-head clinical analysis: BREO ELLIPTA versus ORAPRED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BREO ELLIPTA versus ORAPRED.
BREO ELLIPTA vs ORAPRED
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of fluticasone furoate, a corticosteroid that binds to glucocorticoid receptors to inhibit inflammatory gene transcription, and vilanterol, a long-acting beta2-adrenergic agonist that activates adenylate cyclase leading to bronchodilation.
Prednisolone is a corticosteroid that binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammatory cytokines, immune responses, and adrenal function.
One inhalation (100 mcg fluticasone furoate / 25 mcg vilanterol) once daily via oral inhalation.
5-60 mg orally once daily or divided as 5-15 mg every 4-12 hours; adjust based on response and condition.
None Documented
None Documented
Fluticasone furoate: 24 hours (supports once-daily dosing). Vilanterol: 11 hours (supports once-daily dosing).
4-5 hours (terminal); prolonged in renal impairment (up to 12+ hours in anuria) and hepatic dysfunction; clinical context: dosing interval adjustment in severe renal failure
Fluticasone furoate is eliminated primarily via fecal excretion (approximately 101% of an oral dose) due to biliary clearance, with minimal renal excretion (<1%). Vilanterol is eliminated via metabolism and subsequent renal (approximately 70% of an IV dose) and fecal (approximately 30% of an IV dose) excretion.
Renal: approximately 60-80% as unchanged drug and conjugated metabolites; biliary/fecal: minor (5-10%)
Category C
Category C
Corticosteroid/Beta-2 Agonist Combination
Corticosteroid